GeoVax Labs (GOVX) Depreciation & Amortization (CF) (2010 - 2025)
GeoVax Labs (GOVX) posted quarterly Depreciation & Amortization (CF) of $18230.0 for Q4 2025, down 15.76% year-over-year from $21641.0 in Q4 2024, and up 8.5% quarter-over-quarter from $16802.0 in Q3 2025.
GeoVax Labs (GOVX) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
GeoVax Labs (GOVX) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $18230.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 15.76% year-over-year to $18230.0; the TTM figure through Jun 2026 stood at $51835.0 (down 39.57% YoY), while the FY2025 annual figure was $68756.0, down 27.9% from the prior year.
- Depreciation & Amortization (CF) climbed to $18230.0 in Q4 2025 per GOVX's latest filing, from $16802.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $30408.0 in Q3 2024 and bottomed at $4517.0 in Q1 2021.
- Historically, Depreciation & Amortization (CF) has averaged $16654.9 across 5 years, with a median of $17119.5 in 2023.
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 354.43% — and 2025, when it plunged 44.74%.
- GeoVax Labs' Depreciation & Amortization (CF) stood at $11715.0 in 2021, then increased by 20.11% to $14071.0 in 2022, then surged by 57.86% to $22213.0 in 2023, then dropped by 2.58% to $21641.0 in 2024, then retreated by 15.76% to $18230.0 in 2025.
- Business Quant data shows GOVX's Depreciation & Amortization (CF) at $18230.0 in Q4 2025, $16802.0 in Q3 2025, and $16803.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18,230.00 |
| Dec 31, 2025 | 18,230.00 |
| Sep 30, 2025 | 16,802.00 |
| Sep 30, 2025 | 16,802.00 |
| Jun 30, 2025 | 16,803.00 |
| Jun 30, 2025 | 16,803.00 |
| Mar 31, 2025 | 16,921.00 |
| Mar 31, 2025 | 16,921.00 |
| Dec 31, 2024 | 21,641.00 |
| Dec 31, 2024 | 21,641.00 |
| Sep 30, 2024 | 30,408.00 |
| Sep 30, 2024 | 30,408.00 |
| Jun 30, 2024 | 23,743.00 |
| Jun 30, 2024 | 23,743.00 |
| Mar 31, 2024 | 19,576.00 |
| Mar 31, 2024 | 19,576.00 |
| Dec 31, 2023 | 22,213.00 |
| Dec 31, 2023 | 22,213.00 |
| Sep 30, 2023 | 17,319.00 |
| Sep 30, 2023 | 17,319.00 |